Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Bone Biologics Q3 2026 Results: Net Loss of $618K, Loss Narrows

Bone Biologics Corp reported a net loss of $2,157,341 for the nine months ended September 30, 2026, compared to a loss of $2,424,348 in the prior year period. The company remains in the development stage with zero revenue, focusing its expenditures on research and development for its NELL-1/DBM product candidate.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Net income-0.6-0.7
EPS (diluted, $ a share)$-0.17$-0.37

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, NASDAQ: BBLG. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Bone Biologics Corp: key numbers

Share price
$0.2942Close, Nov 16
Market cap
$997K
Shares outstanding
3.39MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Orthopedic, Prosthetic & Surgical Appliances & SuppliesSIC 3842

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Bone Biologics Corp

All →
5:01 PM ET 8-K
Shareholder Meeting

Bone Biologics Shareholder Meeting

Bone Biologics Corp held its Annual Meeting of stockholders on September 28, 2026, where shareholders elected four directors and ratified Weinberg & Company, P.A. as the independent auditor. Stockholders also approved a potential reverse stock split at a ratio between 1-for-2 and 1-for-10 and authorized the potential issuance of shares underlying warrants in excess of 20% of outstanding stock to comply with Nasdaq rules.

5:01 PM ET 8-K
Nasdaq/NYSE Compliance Notice

Bone Biologics Nasdaq/NYSE Compliance Notice

Bone Biologics Corp received a deficiency notice from Nasdaq on September 10, 2026, because its common stock failed to maintain a minimum bid price of $1.00 for 30 consecutive business days. The company has 180 calendar days, until March 9, 2027, to regain compliance and intends to seek shareholder approval for a reverse stock split to address the deficiency.

Counterparty
Nasdaq
Term
180 days

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.